Shares of Endo International surged nearly 22 percent after the company posted second-quarter earnings exceeded analysts' expectations appointed a new manager.
The global specialty health-care company reported Monday adjusted earnings of 86 cents a share, beating estimates by 12 cents a share. This company posted $921 million in revenue, topping analysts estimates of $863.9 million and according to Thomson Reuters.
We have delivered results across all of our businesses that are on track
Belbuca, This company's opioid drug for management of chronic pain, launched during quarter. It is the first drug approved by the U.S. Food and Drug. Administration that uses a dissolving film to dispense the drug. Patients in the company's trials appeared to have fewer side effects than other pain management regimes.
This company expects full-year earnings between $4.50 and $4.80 per share and revenue between $3.87 billion to $4.03 billion. Analysts expect full-year earnings of $4.55 per share and revenue of $3.93 billion, according to Thomson Reuters.
Комментариев нет:
Отправить комментарий